Michiel Ringkjøbing-elema

Title: Innovations in Pharmaceutical Formulation by Inventor Michiel Ringkjøbing-Elema

Introduction

Michiel Ringkjøbing-Elema, an accomplished inventor based in Jystrup, Denmark, has made significant contributions to the pharmaceutical industry through his innovative approaches to material science. With a total of two patents under his belt, Ringkjøbing-Elema stands out for his dedication to developing solutions that enhance the solubility and stability of therapeutic compounds.

Latest Patents

His latest patents focus on "Controlled Agglomeration," a groundbreaking process for preparing particulate materials. This method enables controlled growth in particle size, particularly beneficial in the formulation of pharmaceutical compositions containing active substances that typically have low aqueous solubility or are prone to chemical decomposition. The patented process involves two primary steps:

1. Spraying a first composition, which consists of a carrier with a melting point of around 5°C or more in liquid form, onto a second solid composition.

2. Mixing or employing mechanical techniques to blend the two compositions, resulting in the desired particulate material.

This innovative approach not only enhances the efficacy of pharmaceutical products but also improves their stability, making them safer and more effective for patient use.

Career Highlights

Michiel Ringkjøbing-Elema is associated with Veloxis Pharmaceuticals A/S, a company known for its focus on developing innovative therapies that improve patient outcomes. His work directly impacts the formulation processes used within the company, paving the way for new advancements in drug delivery systems that can address the needs of patients with challenging therapeutic requirements.

Collaborations

Throughout his career, Ringkjøbing-Elema has collaborated with talented professionals such as Per Holm and Anders Burr. These collaborations are instrumental in driving innovative projects and refining methodologies that lead to successful patent applications and advancements in pharmaceutical technologies. Working alongside such experienced colleagues enhances the collective ability to create cutting-edge solutions in the field.

Conclusion

Michiel Ringkjøbing-Elema exemplifies the spirit of innovation in the pharmaceutical industry with his pioneering work in controlled agglomeration methods. His patents not only advance scientific knowledge but also hold the promise of improving therapeutic options for patients. As he continues to innovate, the impact of his contributions will likely resonate throughout the pharmaceutical landscape for years to come.